Experienced in Myhre Syndrome

Dr. Robert Hopkin

Medical Genetics | Pediatrics
Children's Hospital Medical Center
3333 Burnet Ave, 
Cincinnati, OH 
Experienced in Myhre Syndrome
Children's Hospital Medical Center
3333 Burnet Ave, 
Cincinnati, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Robert Hopkin is a Medical Genetics specialist and a Pediatrics provider in Cincinnati, Ohio. Dr. Hopkin is rated as an Experienced provider by MediFind in the treatment of Myhre Syndrome. His top areas of expertise are Fabry Disease, Neurofibromatosis Type 1 (NF1), Neurofibromatosis, Micrognathia, and Orchiectomy.

His clinical research consists of co-authoring 137 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Myhre Syndrome.

Specialties
Medical Genetics
Pediatrics
Licenses
Clinical Genetics in OH
Hospital Affiliations
Cincinnati Children's Hospital Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Arkansas Health and Wellness
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

CHILDREN'S HOSPITAL MEDICAL CENTER
3333 Burnet Ave, Cincinnati, OH 45229

Additional Areas of Focus

Dr. Hopkin has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy, in Subjects With Fabry Disease (STAAR)
A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy, in Subjects With Fabry Disease (STAAR)
Enrollment Status: Completed
Publish Date: May 15, 2025
Intervention Type: Biological
Study Drug: ST-920
Study Phase: Phase 1/Phase 2
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients With Prader- Willi Syndrome
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients With Prader- Willi Syndrome
Enrollment Status: Terminated
Publish Date: October 19, 2023
Intervention Type: Drug
Study Drug: RAD011
Study Phase: Phase 2/Phase 3
Phase 3 Open-Label Switch Over Study to Assess Safety, Efficacy & PK of Pegunigalsidase Alfa (PRX-102) 2mg/kg IV Every 4 Weeks for 52 Weeks in Fabry Disease Patients Currently Treated With Enzyme Replacement Therapy Fabrazyme® or Replagal™
Phase 3 Open-Label Switch Over Study to Assess Safety, Efficacy & PK of Pegunigalsidase Alfa (PRX-102) 2mg/kg IV Every 4 Weeks for 52 Weeks in Fabry Disease Patients Currently Treated With Enzyme Replacement Therapy Fabrazyme® or Replagal™
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Biological
Study Drug: Pegunigalsidase Alfa
Study Phase: Phase 3
A Randomized, Double Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients With Fabry Disease Previously Treated With Agalsidase Beta
A Randomized, Double Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients With Fabry Disease Previously Treated With Agalsidase Beta
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Biological
Study Drugs: PRX-102 (Pegunigalsidase Alfa), Agalsidase Beta
Study Phase: Phase 3
View 3 Less Clinical Trials

137 Total Publications

Emerging role of complement system in the induction of neuroinflammation in adenylosuccinate lyase deficiency disorder.
Emerging role of complement system in the induction of neuroinflammation in adenylosuccinate lyase deficiency disorder.
Journal: Brain, behavior, & immunity - health
Published: April 19, 2025
Similar Doctors
Advanced in Myhre Syndrome
Dr. Howard Saal
Medical Genetics | Pediatrics
Advanced in Myhre Syndrome
Dr. Howard Saal
Medical Genetics | Pediatrics
3333 Burnet Ave, Ml 4006, 
Cincinnati, OH 
 (0.1 miles away)
513-636-4760
Languages Spoken:
English
See accepted insurances

Howard Saal is a Medical Genetics specialist and a Pediatrics provider in Cincinnati, Ohio. Dr. Saal is rated as an Elite provider by MediFind in the treatment of Myhre Syndrome. His top areas of expertise are Achondroplasia, Acrofacial Dysostosis Rodriguez Type, Treacher Collins Syndrome, and Acrofacial Dysostosis Catania Type.

Experienced in Myhre Syndrome
Dr. Wafa J. Nasser
Pediatrics
Experienced in Myhre Syndrome
Dr. Wafa J. Nasser
Pediatrics
10032 Demia Way, 
Florence, KY 
 (14.5 miles away)
859-647-6700
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Wafa Nasser is a Pediatrics provider in Florence, Kentucky. Dr. Nasser is rated as an Experienced provider by MediFind in the treatment of Myhre Syndrome. Her top areas of expertise are Umbilical Hernia, Delayed Growth, Hernia, and Autism Spectrum Disorder. Dr. Nasser is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hopkin's expertise for a condition
ConditionClose
View All 18 Distinguished Conditions
View All 186 Advanced Conditions
View All 93 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile